TEM logo

TEM
Tempus AI Inc

19,101
Mkt Cap
$14.29B
Volume
9M
52W High
$104.32
52W Low
$31.36
PE Ratio
-69.50
TEM Fundamentals
Price
$82.26
Prev Close
$84.49
Open
$82.23
50D MA
$85.97
Beta
0.00
Avg. Volume
7.08M
EPS (Annual)
-$4.60
P/B
28.78
Rev/Employee
$288,915.83
Loading...
Loading...
News
all
press releases
TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours
Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline following the results.
Zacks·11h ago
News Placeholder
More News
News Placeholder
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for...
Business Wire·14h ago
News Placeholder
Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·1d ago
News Placeholder
Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates
Tempus (TEM) delivered earnings and revenue surprises of +31.25% and +2.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
Tempus Reports Third Quarter 2025 Results
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30...
Business Wire·1d ago
News Placeholder
Omnicell (OMCL) Q3 Earnings and Revenues Surpass Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of +41.67% and +5.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision oncology growth.
Zacks·8d ago
News Placeholder
Tempus to Participate in the Stifel 2025 Healthcare Conference
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13...
Business Wire·9d ago
News Placeholder
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.
Zacks·10d ago
News Placeholder
Tempus to Report Third Quarter 2025 Financial Results on November 4
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The...
Business Wire·16d ago

Latest TEM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.